268 related articles for article (PubMed ID: 30816618)
1. Front-line management of indolent non-Hodgkin lymphoma in Australia. Part 2: mantle cell lymphoma and marginal zone lymphoma.
Cheah CY; Opat S; Trotman J; Marlton P
Intern Med J; 2019 Sep; 49(9):1070-1080. PubMed ID: 30816618
[TBL] [Abstract][Full Text] [Related]
2. Marginal Zone Lymphoma: State-of-the-Art Treatment.
Sindel A; Al-Juhaishi T; Yazbeck V
Curr Treat Options Oncol; 2019 Dec; 20(12):90. PubMed ID: 31807935
[TBL] [Abstract][Full Text] [Related]
3. Marginal zone lymphoma.
Shaye OS; Levine AM
J Natl Compr Canc Netw; 2006 Mar; 4(3):311-8. PubMed ID: 16507274
[TBL] [Abstract][Full Text] [Related]
4. Marginal zone lymphoma: old, new, targeted, and epigenetic therapies.
Joshi M; Sheikh H; Abbi K; Long S; Sharma K; Tulchinsky M; Epner E
Ther Adv Hematol; 2012 Oct; 3(5):275-90. PubMed ID: 23616915
[TBL] [Abstract][Full Text] [Related]
5. Bendamustine-rituximab regimen in untreated indolent marginal zone lymphoma: experience on 65 patients.
Morigi A; Argnani L; Lolli G; Broccoli A; Pellegrini C; Nanni L; Stefoni V; Coppola PE; Carella M; Casadei B; Sabattini E; Cavo M; Zinzani PL
Hematol Oncol; 2020 Oct; 38(4):487-492. PubMed ID: 32594531
[TBL] [Abstract][Full Text] [Related]
6. Management of Marginal Zone Lymphoma: A Canadian Perspective.
Peters A; Keating MM; Nikonova A; Doucette S; Prica A
Curr Oncol; 2023 Feb; 30(2):1745-1759. PubMed ID: 36826096
[TBL] [Abstract][Full Text] [Related]
7. Rare lymphomas in routine practice - Treatment and outcome in marginal zone lymphoma in the prospective German Tumour Registry Lymphatic Neoplasms.
Knauf W; Abenhardt W; Koenigsmann M; Maintz C; Sandner R; Zahn MO; Schnell R; Tech S; Kaiser-Osterhues A; Houet L; Marschner N;
Hematol Oncol; 2021 Aug; 39(3):313-325. PubMed ID: 33942348
[TBL] [Abstract][Full Text] [Related]
8. [Current management of marginal zone lymphomas].
Bonnet C; Lejeune M; Van Kemseke C; Bron D; Beguin Y
Rev Med Suisse; 2015 Aug; 11(483):1549-56. PubMed ID: 26502581
[TBL] [Abstract][Full Text] [Related]
9. Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle-cell lymphomas: a multicentre, randomised, open-label, non-inferiority phase 3 trial.
Rummel M; Kaiser U; Balser C; Stauch M; Brugger W; Welslau M; Niederle N; Losem C; Boeck HP; Weidmann E; von Gruenhagen U; Mueller L; Sandherr M; Hahn L; Vereshchagina J; Kauff F; Blau W; Hinke A; Barth J;
Lancet Oncol; 2016 Jan; 17(1):57-66. PubMed ID: 26655425
[TBL] [Abstract][Full Text] [Related]
10. CD5 expression in marginal zone lymphoma predicts differential response to rituximab or bendamustine/rituximab.
Hsu A; Kurt H; Zayac AS; Olszewski AJ
Leuk Lymphoma; 2022 Jan; 63(1):31-42. PubMed ID: 34467833
[TBL] [Abstract][Full Text] [Related]
11. Marginal zone B-cell lymphoma: lessons from Western and Eastern diagnostic approaches.
Nakamura S; Ponzoni M
Pathology; 2020 Jan; 52(1):15-29. PubMed ID: 31757436
[TBL] [Abstract][Full Text] [Related]
12. State-of-the-art therapeutics: marginal-zone lymphoma.
Bertoni F; Zucca E
J Clin Oncol; 2005 Sep; 23(26):6415-20. PubMed ID: 16155028
[TBL] [Abstract][Full Text] [Related]
13. Marginal zone B-cell lymphoma: A clinical comparison of nodal and mucosa-associated lymphoid tissue types. Non-Hodgkin's Lymphoma Classification Project.
Nathwani BN; Anderson JR; Armitage JO; Cavalli F; Diebold J; Drachenberg MR; Harris NL; MacLennan KA; Müller-Hermelink HK; Ullrich FA; Weisenburger DD
J Clin Oncol; 1999 Aug; 17(8):2486-92. PubMed ID: 10561313
[TBL] [Abstract][Full Text] [Related]
14. Contemporary management of nodal and primary splenic marginal zone lymphoma.
Leslie LA; Feldman TA; McNeill A; Timberg M; Iida H; Goy AH
Expert Rev Hematol; 2019 Dec; 12(12):1011-1022. PubMed ID: 31619091
[No Abstract] [Full Text] [Related]
15. CD5-negative mantle cell lymphoma resembling extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue : a case report.
Hashimoto Y; Omura H; Tanaka T; Hino N; Nakamoto S
J Clin Exp Hematop; 2012; 52(3):185-91. PubMed ID: 23269078
[TBL] [Abstract][Full Text] [Related]
16. Results of Upfront Therapy for Marginal Zone Lymphoma.
Ortega JL; Cabanillas F; Rivera N; Tirado-Gomez M; Hallman D; Pardo WI; Bruno M
Clin Lymphoma Myeloma Leuk; 2017 Dec; 17(12):879-883. PubMed ID: 29042174
[TBL] [Abstract][Full Text] [Related]
17. Primary gastric mantle cell lymphoma in a patient with long standing history of Crohn's disease.
Raderer M; Püspök A; Birkner T; Streubel B; Chott A
Leuk Lymphoma; 2004 Jul; 45(7):1459-62. PubMed ID: 15359648
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of bendamustine and rituximab in splenic marginal zone lymphoma: results from the phase II BRISMA/IELSG36 study.
Iannitto E; Bellei M; Amorim S; Ferreri AJM; Marcheselli L; Cesaretti M; Haioun C; Mancuso S; Bouabdallah K; Gressin R; Tripodo C; Traverse-Glehen A; Baseggio L; Zupo S; Stelitano C; Castagnari B; Patti C; Alvarez I; Liberati AM; Merli M; Gini G; Cabras MG; Dupuis J; Tessoulin B; Perrot A; Re F; Palombi F; Gulino A; Zucca E; Federico M; Thieblemont C
Br J Haematol; 2018 Dec; 183(5):755-765. PubMed ID: 30407629
[TBL] [Abstract][Full Text] [Related]
19. Minimal change disease: an unusual presentation of marginal zone MALT lymphoma.
Inayat F; Law JK; Myers-Gurevitch PM; Seshan SV; Perlman AS
Clin Nephrol; 2016 Mar; 85(3):184-8. PubMed ID: 26636329
[TBL] [Abstract][Full Text] [Related]
20. Primary nodal marginal zone lymphomas of splenic and MALT type.
Campo E; Miquel R; Krenacs L; Sorbara L; Raffeld M; Jaffe ES
Am J Surg Pathol; 1999 Jan; 23(1):59-68. PubMed ID: 9888704
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]